EX-99.1
3
ex99-1.txt
Exhibit 99.1
FOR IMMEDIATE RELEASE
Balchem Corporation Acquires Encapsulation Business from Loders Croklaan
New Hampton, New York, July 1, 2005 - Balchem Corporation (Amex: BCP) today
announced that it has acquired the encapsulation and agglomeration business of
IOI Group, Loders Croklaan USA, LLC. Balchem will continue to operate the
acquired business primarily out of Channahon, IL, with certain product
manufacturing moving to other Balchem operations. This acquired business had
sales of approximately six million dollars in Loders' fiscal year ending June
30, 2005, and was financed from the cash reserves of Balchem.
"The integration of Loders' fluidized bed encapsulation and agglomeration
technologies with our current technologies will provide superior product lines
that will address many needs in the food industry. Additionally, this
acquisition enhances Balchem's strategic initiatives as a supplier of
encapsulated and agglomerated ingredients for use in the pharmaceutical
industry", said Dino A. Rossi, President and CEO of Balchem Corporation.
"We are thrilled to add the innovative products currently produced by Loders to
our portfolio of encapsulated ingredients, and are particularly excited about
expanding our technology capabilities, specifically designed for the
pharmaceutical and supplementation industries. The prospect of developing novel
applications for these markets is significant, and supports our commitment to
technology growth and strengthening our business", said Eric Smith, Balchem's
Vice President, Sales & Marketing, Human Food & Nutrition.
About Balchem: Balchem Corporation consists primarily of three business
segments: ARC Specialty Products, Encapsulated/Nutritional Products and BCP
Ingredients. Through ARC Specialty Products, Balchem provides specialty-packaged
chemicals for use in health care and other industries. The
Encapsulated/Nutritional Products segment provides proprietary
microencapsulation solutions to an expanding variety of applications. BCP
Ingredients, our unencapsulated feed supplements segment, manufactures and
supplies choline chloride and derivatives used primarily in the poultry and
swine industries.
Forward Looking Statements: This release contains forward-looking statements,
which reflect Balchem's expectation or belief concerning future events that
involve risks and uncertainties. Balchem can give no assurance that the
expectations reflected in forward looking statements will prove correct and
various factors could cause results to differ materially from Balchem's
expectations, including risks and factors identified in Balchem's annual report
on Form 10-K for the year ended December 31, 2004. Forward-looking statements
are qualified in their entirety by the above cautionary statement. Balchem
assumes no duty to update its outlook or other forward-looking statements as of
any future date.
Contact: Frank Fitzpatrick, Chief Financial Officer, telephone: (845) 326-5619.

EX - 99 . 1 3 ex99 - 1 . txt Exhibit 99 . 1 FOR IMMEDIATE RELEASE Balchem Corporation Acquires Encapsulation Business from Loders Croklaan New Hampton , New York , July 1 , 2005 - Balchem Corporation ( Amex : BCP ) today announced that it has acquired the encapsulation and agglomeration business of IOI Group , Loders Croklaan USA , LLC . Balchem will continue to operate the acquired business primarily out of Channahon , IL , with certain product manufacturing moving to other Balchem operations . This acquired business had sales of approximately six million dollars in Loders ' fiscal year ending June 30 , 2005 , and was financed from the cash reserves of Balchem . " The integration of Loders ' fluidized bed encapsulation and agglomeration technologies with our current technologies will provide superior product lines that will address many needs in the food industry . Additionally , this acquisition enhances Balchem 's strategic initiatives as a supplier of encapsulated and agglomerated ingredients for use in the pharmaceutical industry " , said Dino A . Rossi , President and CEO of Balchem Corporation . " We are thrilled to add the innovative products currently produced by Loders to our portfolio of encapsulated ingredients , and are particularly excited about expanding our technology capabilities , specifically designed for the pharmaceutical and supplementation industries . The prospect of developing novel applications for these markets is significant , and supports our commitment to technology growth and strengthening our business " , said Eric Smith , Balchem 's Vice President , Sales & Marketing , Human Food & Nutrition . About Balchem : Balchem Corporation consists primarily of three business segments : ARC Specialty Products , Encapsulated / Nutritional Products and BCP Ingredients . Through ARC Specialty Products , Balchem provides specialty - packaged chemicals for use in health care and other industries . The Encapsulated / Nutritional Products segment provides proprietary microencapsulation solutions to an expanding variety of applications . BCP Ingredients , our un encapsulated feed supplements segment , manufactures and supplies choline chloride and derivatives used primarily in the poultry and swine industries . Forward Looking Statements : This release contains forward - looking statements , which reflect Balchem 's expectation or belief concerning future events that involve risks and uncertainties . Balchem can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Balchem 's expectations , including risks and factors identified in Balchem 's annual report on Form 10 - K for the year ended December 31 , 2004 . Forward - looking statements are qualified in their entirety by the above cautionary statement . Balchem assumes no duty to update its outlook or other forward - looking statements as of any future date . Contact : Frank Fitzpatrick , Chief Financial Officer , telephone : ( 845 ) 326 - 5619 .
O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Generic_Info.ANNUAL_REVENUES I-Generic_Info.ANNUAL_REVENUES O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O